Physician Assistant Workforce Grew 28% in USA (2020 To 2024), reaching 189,188 PAs; increased in every state (lease in Alaska 10%, most in SCarolina 48%,(to 2,984 in 2024). In 2024, there were 55.6 PAs/100,000 population https://t.co/VdXP3aM3ga https://t.co/qin2zfuUZe

Muscular strength is a resilience marker relevant to function. A prospective cohort study of 5472 women (mean 79 yrs), showed that greater muscular strength (grip strength, chair stand time) was assoc w/ lower mortality (HR 0.85- 0.67) https://t.co/HEO4r2cdmS https://t.co/Ada3Bnrt0Z

Missed #RheumNowLive 2026? The full meeting is now available On Demand. ✔ 2 days of clinical updates ✔ Expert faculty panels ✔ Speaker slides ✔ Pre-learn modules Watch anytime for $250. Learn from the meeting that kicks off the year in rheumatology. 🔗 Access here: https://t.co/hAvw6a8GQ1

B cell Targeted CAR-T Therapy for Autoimmune Diseases The review by Qi Li and colleagues provides a comprehensive examination of the progression, clinical applications, challenges, and future directions of B-cell-targeted CAR-T therapy across multiple autoimmune conditions. https://t.co/b1SmrOBbBU

Hydroxychloroquine Lowers SLE and RA Hospitalizations A population-based study from British Columbia, Canada, shows that antimalarial adherence was associated with a lower risk of hospital admission in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus https://t.co/vsJDOh09ji

Observational study of 42 Mexican lupus nephritis pts on Immunosuppressives + Calcineurin Inhibitors (CNIs) @ 12 mos complete & partial responses seen in 26% & 36%, w/ signif reduction in proteinuria (2.89 vs 0.72 g/d, p < .001), & transient decrease in eGFR at 12 mo (109 vs 114) https://t.co/Het4GKaTmv

FDA has approved deucravacitinib (Sotyktu) the Treatment of Adults with Active Psoriatic Arthritis based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. Sotyktu is the only tyrosine kinase 2 (TYK2) inhibitor to be approved for PsA https://t.co/8xBrgPfENH

DERM on RheumNow PODCAST (February 2026) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, and other CTD skin disorders. dermatology drugs, biologics, JAKs - their use, efficacy, https://t.co/4ub0MeY9vF

IL-23i fails in GCA? Small RCT of 53 GCA pts (age 71 yrs; 60% new; 40% relapsing GCA) 35 given Guselkumab vs 18 on PBO. Wk 28 GC free remission in 40% vs 33% (P .64), also w/ similar flare rates (31% v 39%). results didnt supportguselkumab use in GCA. https://t.co/AMTmiDBc94 https://t.co/4AQe8HbwQp

Diacerin, an IL-1β blocker, compared to placebo in a 262 pt RCT of knee pain, Knee #OA w/ inflammation. After 24 wks, 88% completed the trial & (vs PBO) diacerein did not improve knee pain (−19.9 vs −18.6 mm). 42% had AE/ GI Sxs were more w/ diacerein (42% vs 25% PBO https://t.co/P2d6IhFw2I

US Epidemiologic survey data from NHANES gout prevalence is incr. in RA pts vs controls (10.3% vs. 4.8%, P < 0.001), increasing trend over time. RA is as an independent risk factor for gout (OR: 2.67), strongest in SNRA. Evidence for the converse may not be as strong. https://t.co/hhRT9NCzVG

Open-access Arthralgia Clinics The early diagnosis of IA, particularly RA, hinges on efficient referral and screening of arthralgia patients. Yet most rheumatology practices are ill-equipped or don't have EACs. This report describes the use of an OAC to manage primary care https://t.co/8ut6LkIUEX